Open AccessCan Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature
Author(s) -
Ali Al Sbihi,
Nouraldeen Manasrah,
Dahlia Sano
Publication year - 2022
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2022_003216
Subject(s) - lenalidomide , medicine , multiple myeloma , covid-19 , series (stratigraphy) , intensive care medicine , pediatrics , virology , disease , paleontology , outbreak , infectious disease (medical specialty) , biology
We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.